This inventor holds 3 USPTO granted patents and 3 EPO patents. Top assignee: Merck Sharp & Dohme LLC. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: David J Witter: Innovator in PRMT5 Inhibitors
Introduction
David J Witter is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of PRMT5 inhibitors. With a total of 3 patents to his name, Witter's work is focused on innovative solutions for treating serious health conditions.
Latest Patents
Witter's latest patents include groundbreaking compounds that serve as PRMT5 inhibitors. The first patent provides a compound selected from various options, including compounds A, B, C, D, and their pharmaceutically acceptable salts, esters, and prodrugs. These compounds are designed to treat cancer, sickle cell disease, and hereditary persistence of fetal hemoglobin (HPFH) mutations. The second patent also presents a compound of Formula (I) along with its pharmaceutically acceptable salts, esters, and prodrugs, aimed at the same therapeutic applications.
Career Highlights
David J Witter is currently associated with Merck Sharp & Dohme LLC, a leading global healthcare company. His role involves extensive research and development in the pharmaceutical sector, focusing on innovative treatments that can significantly improve patient outcomes.
Conclusion
David J Witter's contributions to the field of pharmaceuticals, particularly through his patents on PRMT5 inhibitors, highlight his commitment to advancing medical science. His work continues to pave the way for new treatments that address critical health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile